glp-1 mlm use tripled among non-diabetics, reaching $5.8B in 2022 Nature Made GLP-1 Companion Health

Daily oral drugs will enter the market to join Novo Nordisks oral semaglutide, Rybelsus, in a few years time, including a new group of oral GLP-1s that includes Pfizers danuglipron and Eli Lillys orforglipron (collectively known and the gliprons), with approvals likely from 2027

The medication simply does not interact with human thyroid tissue intensely enough to cause volumetric changes

Im down 50+ lbs in 6 months, plus happy and super energetic

Beyond traditional GLP-1RAs, dual and emerging multi-agonists may have additional metabolic and renal implications

The good news with Pendulum is that its been so much easier for me to step away from the treats after a small bite